FDA Reopened a Path for a One-Time Hunter Syndrome Gene Therapy
Regenxbio says FDA no longer requires additional studies before reviewing Navsunli/RGX-121 for accelerated approval, a potentially important rare-disease regulatory signal.
- Published
- Jun 24, 2026
- Last updated
- Jun 24, 2026
- Last reviewed
- Jun 24, 2026
- Status
- Developing
- Primary source
- Regenxbio
- Verification
- Corroborated reporting
Rapid orientation
The 5-second read
- What happened
- FDA has reopened a potential accelerated-approval path for Regenxbio’s investigational one-time gene therapy for Hunter syndrome.
- Why it matters
- Hunter syndrome is an ultra-rare, severe inherited disease with high unmet need.
- Status
- Developing
- Overclaim risk
- High
- Primary source
- Regenxbio (Company)
- Next thing to watch
- Whether Regenxbio resubmits the BLA, what evidence FDA accepts, and whether the application reaches accelerated approval review.
Claim Check
DevelopingFDA aligned with Regenxbio on a path forward for BLA resubmission of Navsunli/RGX-121 for accelerated approval in Hunter syndrome.
Safe framing
FDA has reopened a potential accelerated-approval path for Regenxbio’s investigational one-time gene therapy for Hunter syndrome.
What happened
Regenxbio says it has aligned with FDA on a path to resubmit its biologics license application for Navsunli, also known as RGX-121. The one-time investigational gene therapy is being developed for Hunter syndrome, a severe inherited disorder also called MPS II.
This is a regulatory opening, not a product approval. FDA review, benefit-risk assessment, manufacturing scrutiny, and any post-approval requirements still stand between a resubmission and patient access.
The wider signal is about evidence in ultra-rare disease. When patient populations are tiny and conventional placebo-controlled trials may be difficult, regulators still have to decide what a persuasive and ethical evidence package looks like.
Why it matters
- Hunter syndrome is an ultra-rare, severe inherited disease with high unmet need.
- The FDA action may influence how rare-disease gene therapies are reviewed when large trials are impractical.
- It connects evidence standards, research ethics, and access in ultra-rare disease.
What not to overclaim
- Navsunli is not approved.
- Hunter syndrome has not been cured.
- A path to review does not mean FDA has determined that the therapy works.
- Resubmission does not guarantee approval or current patient availability.
Signal context
Context
- Primary topic
- Rare Disease Gene Therapy
- Source date
- Jun 22, 2026
- Source stack
- 2 sources
- Current status
- Developing
Evidence trail
Source stack
- PrimaryCompanyJun 22, 2026Regenxbio: Alignment with FDA on path forward for Navsunli BLA resubmission
- IndependentWireJun 23, 2026Reuters: FDA reverses course on Regenxbio rare-disease gene therapy
Keep following the signal